Pharmaceutical composition comprising meglitinide for prevention of hepatic fibrosis

A pharmaceutical composition, technology of liver fibrosis, applied in the field of pharmaceutical composition for prevention, improvement or treatment of liver fibrosis, hepatocyte degeneration or liver cirrhosis, which can solve the problems of non-existence of quick effects

Inactive Publication Date: 2009-03-04
KURUME UNIVERSITY +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, nateglinide has not been reported so far to have other mechanisms of action, such as the improvement of liver tissue inflammation, liver degeneration, and liver fibrosis through the action without insulin secretion.
There are no fast-acting or clinically-professional treatments for liver fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition comprising meglitinide for prevention of hepatic fibrosis
  • Pharmaceutical composition comprising meglitinide for prevention of hepatic fibrosis
  • Pharmaceutical composition comprising meglitinide for prevention of hepatic fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0047] Fatty liver is characterized by abdominal ultrasound diagnosis or abdominal CT examination; various viral markers and autoantibody tests are negative; alcohol drinking experience and drug experience can be excluded; liver biopsy according to Brunt's criteria (Am J Gastroenterol.1999 94:2467- 2474) were diagnosed as NASH; in addition, 5 patients diagnosed with diabetes who could not obtain therapeutic effects from food and exercise therapy were the subjects. At the same time, the test method passed the ethical review of the clinical facility, and the informed consent of all subjects was obtained. For these 5 patients, 90 mg of nateglinide was administered orally three times a day before meals for 16 weeks. In the 0th week and the 12th week or 16th week, as an index of diabetes, the fasting blood sugar level, the blood sugar level of the glucose tolerance test 2 hours, the hemoglobin Alc value, and the liver / spleen ratio based on CT as a liver evaluation of fatty liver H...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed is a pharmaceutical composition for prevention, amelioration or treatment of hepatic fibrosis, hepatocellular degeneration or cirrhosis. The pharmaceutical composition comprises a meglitinide such as nateglinide.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing, improving or treating liver fibrosis, hepatocyte degeneration or liver cirrhosis, containing a drug equivalent to glinides. Specifically, it relates to a pharmaceutical composition containing nateglinide for preventing, improving or treating liver fibrosis, hepatocyte degeneration or liver cirrhosis. Background technique [0002] In most liver diseases such as viral hepatitis, alcoholic hepatitis, and autoimmune hepatitis, cirrhosis, the final form of liver fibrosis, leads to life-threatening diseases such as hepatocellular carcinoma, esophageal and gastric venous tumors. Therefore, there is an urgent need to establish methods for inhibiting liver fibrosis including liver cirrhosis. It has been reported that in viral hepatitis, virus depletion therapy by a combination of interferon and antiviral agent has the effect of improving fibrosis, but in Japan, even the latest combin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/192A61K31/198A61P1/16A61P43/00
CPCA61K31/198A61K31/192A61P1/16A61P43/00
Inventor 上野隆登森田恭代佐田通夫冈野明
Owner KURUME UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap